Important: By clicking “Yes” you are confirming that you are a healthcare professional. OncosilTM is currently unapproved for commercial sale in your region. If you are not a healthcare professional then please click here to Go to the Homepage.
OncoSil Medical Ltd is a Sydney-based medical device company focused on developing a treatment for patients living with pancreatic cancer.
OncoSil Medical has developed a medical device called the OncoSil™ System, and is progressing towards its commercialisation. The device is currently undergoing clinical studies in leading academic sites globally. The clinical data will be used for regulatory submission within targeted markets including Europe, United States, Australia and Asia.
Led by Daniel Kenny, the corporate leadership for OncoSil Medical is a highly experienced group of professionals with many years of successful global drug and device development.
Lead Product – OncoSil™
OncoSil™ is a brachytherapy device that implants a pre-determined dose of beta radiation directly into cancerous tissue. The beta particles emitted by OncoSil™ travel a short distance in tissue causing damage to cancer cell DNA, which renders them incapable of further cell division and proliferation.
OncoSil Medical is currently undertaking clinical studies to investigate the clinical benefit of the addition of OncoSil™ in pancreatic cancer when combined with standard of care chemotherapies.
Unmet need for Pancreatic Cancer treatment
Despite the general increase in the survival of cancer patients, this trend has been slow for pancreatic cancer. Pancreatic cancer is the fourth highest cause of cancer death, and is expected to be the second highest cause of cancer death by 2030 in Western countries 1. Globally, 277,000 new cases of pancreatic cancer are diagnosed annually with the 5-year overall survival rate increasing only by 1% (from 5% to 6%) in the past three decades although there have been improvements in detection 2.
Patients living with pancreatic cancer have limited treatment options with only radical surgery providing a chance for a cure. Treatment options for patients unable to have surgery have an improved outcome with a multimodal approach, combining chemotherapy with radiation therapy 1.
OncoSil™ containing beta-emitting Phosphorous-32, has been developed as a targeted radiation treatment option for patients with unresectable, advanced pancreatic adenocarcinoma and is used in combination with standard of care chemotherapy. This indication remains an area of high unmet medical need and carries a poor prognosis overall. The procedure used for implanting OncoSil™ uses Endoscopic Ultrasound (EUS) guidance which is already used for diagnostic purposes in the setting of pancreatic cancer, and is emerging as an effective technique in the delivery of pancreatic brachytherapy.
 Spadi, R. et al. (2016) Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World Journal of Clinical Oncology Vol 7 Issue 1 pp 27-43.
 Chiorean, E. G and Coveler, A.L. (2015) Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Design, Development and Therapy Vol 9 pp 3529-3545.